Drug Trial Radar · NCT03384940
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
Last checked: Nov 19, 2026Latest source record: Oct 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Feb 23, 2018
Primary completion
Aug 9, 2019
Study completion Nov 10, 2020
Sponsor
- Lead sponsor
- Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo; AstraZeneca
- First posted
- Dec 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Conditions
- Colorectal Neoplasm
Interventions
DS-8201aDrug
DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Best Objective Response Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal CancerTime frame: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 18 months post-dose
- Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal CancerTime frame: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 18 months post-dose
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California
University of Southern California
Los Angeles, California
UCLA Health
Santa Monica, California
Mayo Clinic Jacksonville
Jacksonville, Florida
Karmanos Cancer Institute
Detroit, Michigan
Greenville Health System Cancer Institute
Greenville, South Carolina
West Cancer Center
Germantown, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
MD Anderson Cancer Center, University of Texas
Houston, Texas
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy
Università degli studi della Campania L.Vanvitelli
Naples, Campania, Italy
Oncology Institute Veneto IOV-IRCCS
Padova, Ferrara, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Lombardo, Italy
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kindai University Hospital
Ōsaka-sayama, Osaka, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-Ku, Tokyo, Japan
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitari Clinic de Barcelona
Barcelona, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Royal Marsden Institute (Chelsea)
Chelsea, London, England, United Kingdom
Royal Marsden Institute (Sutton)
Sutton, Surrey, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.